Precipio updates investor presentation; no material new financial data

Precipio, Inc.

Updated investor presentation posted Aug 18, 2025; supersedes version from June 13, 2022.
Presentation reiterates focus on AML rapid test and expansion into broader molecular diagnostics market.
No specific financial guidance or material new disclosures included in the presentation.
Company emphasizes product development platform and go-to-market strategy through distribution partners.
Presentation includes forward-looking projections on revenue mix and gross margins but without quantified targets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.